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(57) ABSTRACT 
A compound and method for using the compound to reduce 
injury associated With ischemia and reperfusion of mamma 
lian organs such as the heart. The compound may be 
administered as part of a preconditioning strategy Which 
reduces the extent of injury and improves organ function 
folloWing cessation and restoration of blood ?oW. The 
compound may be used in preparation for planned ischemia 
or in a prophylactic manner in anticipation of further 
ischemic events. 
24 Claims, 4 Drawing Sheets 
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PROTECTION AGAINST ISCHEMIA AND 
REPERFUSION INJURY 
FIELD OF THE INVENTION 
The invention relates to compounds protective against 
ischemia and reperfusion injury, particularly in the 
myocardium, and their use. 
BACKGROUND 
Tissues deprived of blood and oxygen undergo ischemic 
necrosis or infarction With possible irreversible organ dam 
age. In some circumstances, hoWever, such as during cardiac 
surgery, it is desirable to interrupt the normal myocardial 
contractions (cardioplegia) and actually induce ischemia. 
Such elective or obligatory ischemia occurs in the presence 
of safeguards such as cardioplegia-induced cardiac arrest 
and hypothermia. While these safeguards provide consider 
able myocardial protection, alteration of myocardial ener 
getics (stunning) and poor postoperative ventricular function 
still remain signi?cant problems. 
Once the How of blood and oxygen is restored to the organ 
or tissue (reperfusion), the organ does not immediately 
return to the normal preischemic state. Reperfused postis 
chemic non-necrotic myocardium is poorly contractile and 
has reduced concentrations of high energy nucleotides, 
depressed subcellular organelle function and membrane 
damage that resolves only sloWly. Although reperfusion 
restores oxygen and reverses ischemia, repletion of high 
energy nucleotides such as adenosine triphosphate (ATP) 
and reversal of ischemic membrane damage is sloW, and 
contractile function may be profoundly depressed for a long 
period. Just minutes of ischemia causes loss of myocardial 
systolic Wall thickening for hours. Longer periods of revers 
ible ischemia may depress contractility for days. Studies 
con?rm that, despite restoration of myocardial How and a 
quick recovery of myocardial oxygen consumption (MVO2) 
folloWing ischemia, there is only very sloW recovery of 
myocardial contractile function. The problems are exacer 
bated in high risk patients, such as those With poor preop 
erative ventricular function, recent myocardial infarction or 
left ventricular hypertrophy. These same problems also 
occur during organ storage for cardiac transplant, under 
Which there are time constraints due to the limits of myo 
cardial preservation. 
Postischemic dysfunction may be due to a variety of 
factors. Oxygen free radicals may play a role, as generation 
of free radicals in stunned myocardium has been demon 
strated and free radical scavengers have been shoWn to 
attenuate contractile dysfunction. Impaired intracellular cal 
cium handling and calcium overload during early reperfu 
sion may contribute to postischemic dysfunction; While 
calcium infusions enhance contractility in both normal and 
postischemic myocardium, ischemia as short as a feW min 
utes produces an impairment in sarcoplasmic reticulum 
calcium transport and a shift of the calcium ATPase activity. 
Postischemic myocardium is also associated With reduced 
concentrations of myocardial high-energy phosphates and 
adenine nucleotides, as obligatory reduction in myocardial 
ATP content during ischemia occurs as myocytes utiliZe ATP 
for maintenance of cellular integrity. Since ATP is essential 
for myocardial contraction and relaxation, ATP depletion 
may have detrimental effects upon postischemic myocardial 
functional recovery. 
The high volume of cardiac-related surgeries, both elec 
tive and emergency procedures and including cardiac 
transplants, lead to the above-described problems. Thus, 
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2 
methods and agents to provide protection against myocardial 
ischemia and to avoid post ischemic dysfunction are needed. 
SUMMARY OF THE INVENTION 
The invention is directed to an agent and a method of 
using the agent to reduce the injury associated With ischemia 
and reperfusion of organs such as the heart. The compound 
is Tyr-D-Leu-Phe-Ala-Asp-Val-Ala-Ser-Thr-Ile-Gly-Asp 
Phe-Phe-His-Ser-Ile-NH2 SEQ ID NO:1, hereinafter 
compound-D. Administration of compound-D SEQ ID 
NO:1, particularly prior to an ischemic event, reduces tissue 
necrosis and preserves organ function. 
In one embodiment, a method of protecting against 
ischemia and reperfusion injury in a mammal is disclosed. 
An effective concentration of compound-D SEQ ID NO:1 is 
administered to the mammal in a pharmaceutically accept 
able formulation prior to the onset of ischemia, for example, 
24 hours prior to ischemia. In other embodiments, 
compound-D SEQ ID NO:1 is administered substantially 
concurrent With the onset of ischemia, during an ischemic 
episode, or post-ischemia. The formulation may be admin 
istered parenterally at a concentration in the range of about 
1—20 mg/kg of body Weight. 
The invention is also directed to a method to prevent 
damage to an isolated organ, for example, a heart for 
transplant. The isolated organ is exposed to a preservative 
solution containing an effective amount of compound-D 
SEQ ID NO:1. The concentration of compound-D SEQ ID 
NO:1 in the preservative solution for a heart is about 100 
pM. 
The invention is additionally directed to a method for 
reducing effects of an ischemic episode in a mammal by 
administering an effective concentration of compound-D 
SEQ ID NO:1 in a pharmaceutically acceptable carrier. 
Administration is prior to or substantially concurrently With 
the onset of ischemia, or one hour post cerebral ischemia. 
The invention is further directed to a composition that 
protects a mammalian organ from injury. The composition 
contains compound-D SEQ ID NO:1. Compound-D may be 
naturally occurring or may be synthesiZed. 
The invention is also directed to an organ preservative 
solution that contains compound-D at a concentration effec 
tive to protect the organ, such as a heart, from ischemic 
injury. 
These and other advantages of the invention Will be 
apparent in light of the folloWing draWings and detailed 
description. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a histogram shoWing myocardial infarction siZe 
in control and treated animals. 
FIG. 2 is a histogram shoWing post-ischemic release of 
creatine kinase in control and treated animals. 
FIG. 3 is a histogram shoWing post-ischemic release of 
troponin I in control and treated animals. 
FIG. 4 is a graph shoWing end diastolic pressure in the left 
ventricle of control and treated animals. 
FIG. 5 is a graph shoWing functional recovery in control 
and treated animals. 
FIG. 6 is a graph shoWing coronary flow in control and 
treated animals. 
FIG. 7 is a histogram shoWing the effect of naltrexone on 
infarct siZe in animals pretreated With compound-D SEQ ID 
NO:1. 
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FIG. 8 is a histogram showing the effect of glibenclamide 
on vas deferens contractility in animals treated With 1,000 
nM compound-D SEQ ID NO: 1. 
FIG. 9 is a histogram shoWing the effect of glibenclamide 
on vas deferens contractility in animals treated With 2,000 
nM compound-D SEQ ID NO:1. 
DETAILED DESCRIPTION 
The invention is directed to a compound that has a 
salutary effect on cardiac function folloWing ischemia, and 
methods of using the compound. The compound may be 
administered directly to an individual, and is particularly 
effective When administered 24 h prior to the onset of 
ischemia. This may occur, for example, prior to scheduled 
cardiac surgery. The compound may also be included in a 
preservative solution for an isolated organ, such as a heart or 
liver being maintained viable for transplant. 
The compound is a peptide having the sequence Tyr-D 
Leu-Phe-Ala-Asp-Val-Ala-Ser-Thr-lie-Gly-Asp-Phe-Phe 
His-Ser-IIe-NH2 SEQ ID NO: 1, hereinafter referred to 
compound-D. The peptide may be produced by a number of 
methods, such as using an automated peptide synthesiZer, 
through recombinant molecular techniques, or isolated from 
a naturally occurring source, as is knoWn to one skilled in the 
art. Compound-D SEQ ID NO:1 has a molecular Weight of 
1,902 daltons. Compound-D SEQ ID NO:1 is insoluble in 
Water or saline, but may be solubiliZed by adding 100 pM of 
a solution comprised of ethanol, propylene glycol, and 1 N 
NaOH in a 1:111 ratio, With sterile physiological saline then 
used to obtain the appropriate concentration. The initial 
alkaline pH is adjusted to 7.4 With 1 N HCI. 
Compound-D SEQ ID NO:1 that has been solubiliZed 
may be administered by parenteral means, for example, by 
intravenous injection. In one embodiment, administration of 
compound-D SEQ ID NO:1 is at the time of induced 
ischemia, but may also be added during or even after an 
ischemic event. For administration into a mammal, a dose of 
about 1—20 milligrams per kilogram (mg/kg) is useful. For 
administration into a tissue or organ preservation solution, a 
concentration of about 100 pM is useful. 
Compound-D SEQ ID NO:1 may be administered directly 
into a mammal, either alone or in combination With other 
substances. Alternatively, it may be added as a component of 
a solution used to maintain the viability of isolated organs, 
such as an additive to cardioplegia and other organ preser 
vation solutions. In one embodiment, compound-D SEQ ID 
NO:1 is coadministered as an adjuvant With other com 
pounds or strategies that are designed to protect organs from 
ischemia. As an example, compound-D SEQ ID NO:1 may 
be administered With agents that affect nitric oxide (NO) 
synthase, such as arginine hydrochloride. Arginine hydro 
chloride is knoWn to prevent the decline in cardiac function 
folloWing an ischemic episode. 
The folloWing description demonstrates use and ef?cacy 
of compound-D SEQ ID NO:1 in a variety of systems. 
PERFUSED HEART 
Compound-D SEQ ID NO:1, at a dose of 2 mg/kg and 
solubiliZed as described above, Was administered by tail 
vein injection into rats Weighing betWeen about 350—400 g 
(number of animals (n)=6). Control rats (n=6) Were injected 
in the same manner With an equal volume of 0.9% NaCI. 
After 24 h, the hearts from both treated and control animals 
Were excised and perfused in a modi?ed Langendorff per 
fusion apparatus at 37° C. using oxygenated Krebs 
Henseleit buffer as the perfusate, as knoWn to one skilled in 
the art. Coronary perfusion pressure Was maintained at 70 
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mm Hg by regulating coronary ?oW. All hearts Were paced 
at 5.5 HZ (300 beats per minute, bpm) except during 
ischemia. A saline-?lled balloon Was inserted in the left 
ventricle to measure developed pressure (DP) and end 
diastolic pressure (EDP) in mm Hg. After 15 min 
equilibration, both groups Were subjected to 20 min Zero 
?oW global ischemia, and then Were reperfused for 120 min. 
Left ventricles Were isolated and divided into three seg 
ments along their short axis, stained With triphenyltetraZo 
lium chloride, and stored in formalin. Infarct siZe Was 
measured on digitiZed images and expressed as a per centage 
of myocardium. Data Were expressed as mean plus or minus 
standard error of the mean (:SEM) and Were analyZe using 
a paired Student’s t-Test. Con?dence limits Were established 
at 95%. 
The results are shoWn in FIG. 1, Which is a histogram of 
the infarct siZe in hearts from both animals receiving only 
saline (control, solid bar) and in animals treated With 
compound-D SEQ ID NO:1 at 2.0 mg/kg (treated, open bar) 
24 h prior to 20 min ischemia and 120 min reperfusion. 
Pretreatment of animals With compound-D SEQ ID NO:1 
signi?cantly decreased the percent of infarct siZe (p<0.05). 
Control rats had a mean infarct siZe of 27:5%, While rats 
pretreated With compound-D had a reduced mean infarct 
siZe of 12:3%. 
Compound-D SEQ ID NO:1 pretreatment also signi? 
cantly decreased total creatine kinase (CK) and the cardiac 
form of troponin I (cTn-1) values folloWing 20 min 
ischemia, as shoWn in FIGS. 2 and 3, respectively. CK is an 
enZyme that is normally found in muscles such as the heart 
(that is, in myocytes), but is released during severe muscle 
trauma such as occurs in a myocardial infarction. Thus, 
measurement of CK is an indicator of the degree of muscle 
damage or trauma. Similarly, cTn-l is a protein associated 
speci?cally With cardiac muscle, and an increase in cTn-1 
indicates myocardial damage. 
FIG. 2 is a histogram shoWing CK released during rep 
erfusion of isolated rat hearts after 20 min ischemia in rats 
treated 24 h prior to ischemia With 2.0 mg/kg compound-D 
SEQ ID NO:1. The solid bars represent control animals 
(n=6) and the open bars represent treated animals (n=6). 
FIG. 3 is a histogram shoWing cTn-l released during rep 
erfusion of isolated rat hearts after 20 min ischemia in rats 
treated 24 h prior to ischemia With 2.0 mg/kg compound-D 
SEQ ID NO:1. The solid bars represent control animals 
(n=6) and the open bars represent treated animals (n=6). At 
each time point during reperfusion Where samples Were 
collected for CK and cTn-1 analysis (1, 1 5, 30, 60, 90 and 
120 min reperfusion), CK levels in control rats Were higher 
than CK levels in treated rats, and Tn—1 levels in control rats 
Were higher than Tn—1 levels in treated rats. This indicated 
that pretreatment With compound-D SEQ ID NO:1 
decreased the damage to the myocardium, as compared to 
animals that did not receive compound-D SEQ ID NO:1. 
Compound-D SEQ ID NO:1 pretreatment also resulted in 
improved postischemic ventricular function. FIG. 4 is a 
graph of end diastolic pressure (EDP) in mm/Hg in the left 
ventricle during reperfusion of isolated rat hearts after 20 
min ischemia in rats treated 24 h prior to ischemia With 2.0 
mg/kg compound-D SEQ ID NO:1. Open squares are from 
treated animals, and solid circles are from control animals. 
FIG. 5 is a graph shoWing percent of functional recovery 
during reperfusion of isolated rat hearts after 20 min 
ischemia in rats treated 24 h prior to ischemia With 2.0 
mg/kg compound-D SEQ ID NO:1. Open squares are from 
treated animals, and solid circles are from control animals. 
Differences in recovery of developed pressure (DP) of 
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compound-D SEQ ID NO:1 treated hearts remained statis 
tically signi?cant to 90 min following initiation of 
reperfusion, as shoWn in FIG. 4, and in end diastolic 
pressure to 20 min following initiation of reperfusion, as 
shoWn in FIG. 5. Left ventricular functional recovery (% 
recovery of baseline preischemic developed pressure during 
reperfusion) Was markedly improved in treated animals 
(open squares) compared to control animals (solid circles) to 
90 min of reperfusion. As shoWn in FIG. 6, coronary How 
Was not signi?cantly different betWeen control animals 
(solid circles) and compound-D SEQ ID NO:1 treated 
animals (open squares). 
These results shoW that in a normoXic, isolated perfused 
rat heart preparation, administration of compound-D can 
confer cardioprotection When administered 24 h prior to 
planned ischemia. The salutary effects on the post-ischemic 
myocardium include reduced infarct siZe, decreased release 
of both creatine kinase and cardiospeci?c troponin 1, and 
improved ventricular performance. 
FIG. 7 shoWs the effect of naltreXone, a universal opioid 
antagonist, on infarct siZe. Groups of rats Were pretreated 24 
h prior to ischemia With either compound-D SEQ ID NO:1 
at a dose of 2.0 mg/kg (n=6), naltreXone at a dose of 3 mg/kg 
(n=6), or a combination of compound-D SEQ ID NO:1 at a 
dose of 2.0 mg/kg and naltreXone at a dose of 3 mg/kg (n=6). 
Control rats (n=6) received vehicle (1 :1 :1 solution of 1 N 
NaOHzpropyleneglycol:ethanol, readjusted to 7.4 With HCI) 
only. After 24 h pretreatment, isolated rat hearts Were 
subjected to 20 min ischemia folloWed by 120 min reper 
fusion. 
As shoWn in FIG. 7, these data indicate that naltreXone 
administered in combination With compound-D SEQ ID 
N011 did not block the cardioprotective effects of 
compound-D SEQ ID NO:1. In fact, the data support a 
synergistic cardioprotective effect from administration of a 
combination of compound-D SEQ ID NO:1 and naltreXone. 
Administration of compound-D SEQ ID NO:1 reduced 
infarct siZe from about 27% in the control group (solid bar) 
to about 13% in the compound-D SEQ ID NO:1 treated 
group (open bar) (p=0.05). The combined preischemic 
administration of compound-D SEQ ID NO:1 and naltreX 
one (doWnWard hatched bar) red to about 10% When com 
pared to the control group (p=0.05). Additionally, these data 
demonstrate that compound-D SEQ ID NO:1 does not 
operate via delta opioid receptors, since naltreXone, an 
opioid receptor antagonist, did not prevent compound-D 
SEQ ID NO:1 activity in reducing infarct siZe (about 14.5% 
versus about 13%, respectively). 
Mouse Vas Deferens 
UtiliZing a mouse vas deferens (m.v.d.) assay, 
compound-D SEQ ID NO: 1, it Was demonstrated that opioid 
receptor binding requires activation and/or opening of KATP 
channels. Glibenclamide, a KATP channel blocker, blocked 
the inhibition of contraction of mouse vas deferens induced 
by compound-D SEQ ID NO:1. With reference to FIG. 8, the 
effect of administration of 1000 nM compound-D SEQ ID 
NO:1 alone (open bar) versus 1000 nM compound-D SEQ 
ID NO:1 With 6000 nM glibenclamide (hatched bar) on 
contractility of mouse vas deferens (m.v.d.) (n=6) is shoWn. 
Glibenclamide restored m.v.d. contractions Which 
compound-D SEQ ID NO:1 had suppressed. FIG. 8 shoWs 
that 1000 nM compound-D SEQ ID NO:1 suppressed con 
tractility to above 100%. FIG. 8 also shoWs that differences 
betWeen control contractions and 1000 nM compound-D 
SEQ ID NO: 1, as Well as control versus 6000 nM 
glibenclamide, and 1000 nM compound-D SEQ ID NO:1 
versus 6000 nM glibenclamide are statistically signi?cant. 
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FIG. 9 shoWs the effect of administration of 2000 nM 
compound-D alone (open bars) versus 2000 nM 
compound-D SEQ ID NO:1 With 6000 nM glibenclamide 
(hatched bar) on contractility of m.v.d. (n=2). 
These results demonstrate that the effect of compound-D 
SEQ ID NO:1 requires opening and/or activation of KATP 
channels since glibenclamide, a potassium channel blocker, 
effectively blocked the smooth muscle inhibition of contrac 
tion induced by compound-D SEQ ID NO:1 in the m.v.d. 
assay. The possibility therefore eXists that administration of 
compound-D SEQ ID NO:1 and interventions directly tar 
geted at opening KATP channels by drugs such as nicorandil 
or diaZoXide, or anesthetics such as iso?urane, could be 
effective approaches for pharmacologically duplicating both 
short term and long term (second WindoW) ischemic pre 
conditioning. Thus, preinfusions of compound-D SEQ ID 
NO:1 may provide extended protection to the ischemic 
myocardium in a variety of clinical scenarios. 
Compound-D, SEQ ID NO:1 has also been shoWn to be 
effective in reducing ischemic effects When administered 1 
h after an episode of induced cerebral ischemia. A solution 
of 100 ML of either vehicle alone (control) or compound-D 
(treated) at a concentration of 1 mg/ml Was administered 
either 1 h before cerebral ischemia or 1 h after cerebral 
ischemia (n=6 in each group). In animals receiving 
compound-D before ischemia, there Were no signi?cant 
differences in infarct volume (control 91:10 mm3 versus 
treated 89:11 mm3) or neurological score (control group 
1.93:0.29 versus treated group 1.95:0.33). HoWever, When 
compound-D Was administered 1 h post ischemia, there 
Were signi?cant difference in both the infarct volume 
(control group 90:13 mm3 versus treated group 5619 mm3) 
and the neurological score (control group 1.91:0.27 versus 
treated group 1421028) in rats receiving compound-D SEQ 
ID NO:1 versus the control group. The mean arterial blood 
pressure, P02, pCO2, pH and cerebral blood ?oW shoWed no 
signi?cant differences in control versus treated groups When 
compound-D SEQ ID NO:1 Was administered either pre or 
post-cerebral ischemia (data not shoWn). These results sug 
gest a therapeutic role for compound-D SEQ ID NO:1 in 
mitigating the effects of a cerebral ischemic episode that is 
in progress or that has occurred. 
In summary, a compound that is administered to a mam 
mal to reduce the injury associated With ischemia and 
reperfusion of organs such as the heart is disclosed. The 
compound is Tyr-D-Leu-Phe-Ala-Asp-Val-Ala-Ser-Thr-Ile 
Gly-Asp-Phe-Phe-His-Ser-Ile-NH2 SEQ ID NO:1. Admin 
istration prior to an ischemic event reduces tissue necrosis 
and preserves organ function, as measured by standard 
physiological indices of organ function. The compound may 
be administered in a time frame from 24 h up to 15 min prior 
to planned ischemia, or even during an ischemic period. 
It should be understood that the embodiments of the 
present invention shoWn and described in the speci?cation 
are only preferred embodiments of the inventors Who are 
skilled in the art and thus are not limiting in any Way. For 
example, compound-D SEQ ID NO:1 may be used as a 
protective agent for organs other than the heart. Organs 
isolated for transplant such as kidney, liver, lung, cornea, etc. 
may have enhanced viability after eXposure to compound-D 
SEQ ID NO:1. Similarly, compound-D SEQ ID NO:1 may 
be administered to individuals in Which ischemia to organs 
other than the heart has occurred or Will occur. Therefore 
various changes, modi?cations or alterations to these 
embodiments may be made or resorted to Without departing 
from the spirit of the invention and the scope of the 
folloWing claims. 
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SEQUENCE LISTING 
<l60> NUMBER OF SEQ ID NOS: 1 
<210> SEQ ID NO 1 
<2ll> LENGTH: 17 
<2 12> TYPE: PRT 
<213> ORGANISM: XYZ 
<220> FEATURE: 
<221> NAME/KEY: PEPTIDE 
<222> LOCATION: (0) . . . (0) 
<221> NAME/KEY: MODIREs 
<222> LOCATION: ( 1) . . . (0) 
<223> OTHER INFORMATION: Xaa = D-Leu 
<400> SEQUENCE: 1 
Tyr Xaa Phe Ala Asp Val Ala Ser Thr Ile Gly Asp Phe Phe His Ser 
1 5 l0 
Ile 
15 
What is claimed is: 
1. Acomposition comprising compound-D SEQ ID NO:1. 
2. The composition of claim 1 wherein compound-D SEQ 
ID NO:1 is obtained by in vitro synthesis. 
3. The composition of claim 1 Wherein compound-D SEQ 
ID NO:1 is isolated from a natural source. 
4. A solution to preserve viability of an isolated organ 
comprising compound-D SEQ ID NO:1 at a concentration 
effective to protect the organ from ischemic injury. 
5. The solution of claim 3 Wherein the organ is selected 
from the group consisting of heart, liver, kidney, cornea, 
lung, and combinations thereof. 
6. A method of protecting against ischemia and reperfu 
sion injury in a mammal comprising administering an effec 
tive amount of compound-D SEQ ID NO:1 to the mammal 
in a pharmaceutically acceptable formulation. 
7. The method of claim 6 Wherein administration is prior 
to onset of ischemia. 
8. The method of claim 7 Wherein administration is about 
24 hours prior to onset of ischemia. 
9. The method of claim 6 Wherein compound-D SEQ ID 
NO:1 is administered as a solution. 
10. The method of claim 6 Wherein compound-D SEQ ID 
NO:1 is administered parenterally. 
11. The method of claim 6 Wherein compound-D SEQ ID 
NO: 1 is administered at a concentration in the range of about 
2 mg/kg of body Weight of the mammal. 
12. The method of claim 6 Wherein compound-D SEQ ID 
NO:1 is administered to protect against myocardial 
ischemia. 
13. The method of claim 2 Wherein said myocardial 
ischemia occur during surgery. 
25 
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14. The method of claim 6 Wherein the formulation 
further includes a compound having an anti-ischemic effect. 
15. The method of claim 14 Wherein the compound affects 
nitric oXide synthase. 
16. The method of claim 15 Wherein the compound is 
arginine hydrochloride. 
17. The method of claim 6 Wherein compound-D SEQ ID 
NO:1 is administered at a concentration in the range of about 
1—20 mg/kg of body Weight. 
18. A method to preserve at least one isolated organ 
comprising eXposing the organ to a solution comprising a 
preservative and an effective amount of compound-D. 
19. The method of claim 18 Wherein the organ is selected 
from the group consisting of heart, liver, kidney, cornea, 
lung and combinations thereof. 
20. The method of claim 18 Wherein compound-D SEQ 
ID NO:1 is at a concentration of about 100 NM in the 
solution. 
21. A method for reducing effects of ischemia in a 
mammal comprising administering an effective amount of 
compound-D SEQ ID NO:1 in a pharmaceutically accept 
able carrier to the mammal. 
22. The method of claim 21 Wherein compound-D SEQ 
ID NO:1 is administered prior to ischemia. 
23. The method of claim 21 Wherein compound-D SEQ 
ID NO:1 is administered substantially concurrently With 
onset of ischemia. 
24. The method of claim 21 Wherein compound-D SEQ 
ID NO: 1 is administered after one hour of cerebral ischemia. 
UNITED STATES PATENT AND TRADEMARK OFFICE 
CERTIFICATE OF CORRECTION 
PATENT NO. : 6,316,411 B1 Page 1 of 2 
DATED : November 13, 2001 
INVENTOR(S) : Oeltgen et al. 
It is certified that error appears in the above-identi?ed patent and that said Letters Patent is 
hereby corrected as shown below: 
Column 3 
Line 19, “Tyr-D-Leu-Phe-Ala-Asp-Val-Ala-Ser-Thr-lie-Gly-Asp-Phe-Phe-His-Ser-IIe 
NH2” should be -- Tyr-D-Leu-Phe-Ala-Asp-Val-Ala-Ser-Thr-Ile-Gly-Asp-Phe-Phe-His 
Ser-Ile-NH2 - 
Line 31, change “HCI” to -- HCl - 
Line 62, change “NaCI” to -- NaCl - 
Column 4 
Line 11, change “per centage” to -- percentage - 
Line 14, change “analyze” to -- analyzed - 
Column 5 
Line 18, change “troponin 1” to -- troponin l - 
Line 27, change “HCI” to -- HCl - 
Line 42, change “red to about” to -- reduced infarct size to about - 
Column 6 
Line 38, change “pre or post-cerebral” to -- pre- or post-cerebral - 
Column 7 
Line 33, change “The solution of claim 3 wherein” to -- The solution of claim 4 
wherein - 
Line 49, change “concentration in the range of about 2 mg/kg of body weight” to 
-- concentration of 2 mg/kg of body weight - 
Line 54, change “The method of claim 2 wherein said myocardial ischemia occur during 
surgery.” to -- The method of claim 12 wherein said myocardial ischemia occurs during 
surgery. - 
Column 8 
Line 31, change “range of about 1-20 mg/kg of body weight.” to -- range of 1-20 mg/kg 
of body weight of the mammal. - 
Line 35, change “effective amount of compound-D.” to -- effective amount of 
compound-D SEQ ID NO:1. - 
UNITED STATES PATENT AND TRADEMARK OFFICE 
CERTIFICATE OF CORRECTION 
PATENT NO. : 6,316,411 B1 Page 2 of 2 
DATED : November 13, 2001 
INVENTOR(S) : Oeltgen et al. 
It is certified that error appears in the above-identi?ed patent and that said Letters Patent is 
hereby corrected as shown below: 
Column 8 cont’d 
Line 41, change concentration of about 100 ,uM” to -- concentration of 100 ,uM - 
Line 50, change “administered substantially concurrently With onset” to -- administered 
with onset - 
Signed and Sealed this 
Tenth Day of September, 2002 
Arresr: 
JAMES E. ROGAN 
Arresting O?’icer Direcror ofrhe United States Patent and Trademark O?‘ice 
